Clinical Trial Update: Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating duvelisib in combination with romidepsin or with bortezomib for relapsed/refractory T-cell lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• T-cell Lymphomas

Drugs mentioned

• Bortezomib (Velcade) (Bortezomib)
• Duvelisib (Copiktra) (duvelisib)
• Romidepsin (Istodax) (romidepsin)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas | Phase 1 | Status: COMPLETED